Aliskiren + Valsartan (Aliskirenum + Valsartanum)

Selective inhibitor of renin of non-peptide structure, blocks the conversion of angiotensin into angiotensin I, reducing the plasma renin level, angiotensin I and angiotensin II.

Renin is excreted by the kidneys with a decrease in renal perfusion and the volume of circulating blood. Once in the bloodstream, renin cleaves angiotensin to an inactive decapeptide of angiotensin I, which, in turn, with the help of an angiotensin-converting enzyme is converted into active octapeptide angiotensin II, which causes vasoconstriction and stimulates the release of adrenal catecholamines from the adrenal medulla, also enhances the reabsorption of sodium and aldosterone ions, which increases blood pressure. By increasing the level of angiotensin II there is an expression of markers and mediators of inflammation and fibrosis of the organ. In addition, angiotensin II inhibits the release of renin, adversely affecting the system.As a result, increased activity of renin leads to an increased risk of cardiovascular complications.

The action of inhibitors of renin leads to a compensatory increase in the concentration of renin in the blood plasma. The action of aliskiren neutralizes the feedback effect, which leads to a persistent decrease in plasma renin activity.